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Background: Diagnostic value of Bone marrow (BM) biopsies for fever of unknown ori-
gin (FUO) remain controversial and BM biopsies are difficult to perform in young 
patients. Our study aimed to elucidate the diagnostic yield of BM biopsies in FUO pa-
tients of all age, particularly for diagnosing hematological malignant diseases.
Methods: The medical records of 150 patients, hospitalized between January 1, 2008 
and June 30, 2013, who underwent BM biopsies were evaluated to determine the cause 
of FUO. FUO was defined as fever (38.3oC, 101oF) either on several occasions during 
the 3 hospital days without a clear cause, after 1 week of invasive investigation, or after 
3 outpatient visits. BM-specific diagnoses included those determined by BM biopsies 
(i.e., leukemia, lymphoma, myeloproliferative disease, myelodysplastic syndrome, aplas-
tic anemia, and hemophagocytic lymphohistiocytosis).
Results: The final diagnoses of 24 patients (16%) were determined by BM biopsies; the 
majority included hematologic diseases and malignant neoplasms. Low hemoglobin lev-
els, thrombocytopenia, bicytopenia, increased Lactate dehydrogenase (LDH) and ferritin 
levels, and ultrasonographic/computed tomographic abnormalities were significant risk 
factors (P＜0.05). The young patient group (＜18 years old) was safer from the tendency 
of BM biopsy diagnosis compared to adult patient group (＞40 years old).
Conclusion: Some laboratory abnormalities were related to the BM biopsy diagnostic 
yield. Furthermore, pediatric age was an important factor for deciding to do not perform 
excessive BM biopsies in FUO cases.
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Introduction
Despite advances in diagnostic techniques and research, 
determining the causes of fever of unknown origin (FUO) 
remains an unassailable challenge. In 1961, Petersdorf and 
Beeson established the definition of FUO [1]: an illness with 
a duration ＞3 weeks, fever ＞38.38oC (101.8oF) on at least 
2 occasions, and an uncertain diagnosis after 1 week of 
hospitalization. However, a modified definition of the FUO 
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criteria was suggested in 1991, which reflected the current 
trend of conducting aggressive investigations during the 
early stages of febrile status and advancements in diag-
nostic tools [2]. Many non-invasive and invasive proce-
dures, including laboratory tests, imaging studies, and biop-
sies were performed to determine the causes of FUO [3-6].
Traditionally, bone marrow (BM) biopsy has been one 
of the procedures to determine the cause of FUO. 
Moreover, hematologic malignancies and occult cancers or 
infections cannot be diagnosed without BM biopsies. BM 
biopsies have been considered as a secondary plan among 
various diagnostic methods due to its invasive character [7]. 
Previous studies have been conducted regarding the accu-
racy of the diagnostic yield of BM biopsies, which is con-
sidered as a relatively invasive procedure for FUO work-up. 
However, most of these previous studies were restricted to 
patients with FUO and human immunodeficiency virus 
(HIV) or mycobacterial infection, not immunocompetent 
patients [8,9].
In a recent study, anemia and thrombocytopenia were 
identified as predictable factors for effective BM biopsy in 
immunocompetent patients with FUO; the diagnostic yield 
was observed to be 23.7%, which was quite high in the 
modern FUO workup era [10]. Moreover, in a more recent 
study, the positive predictive factor of BM biopsies as use-
ful diagnostic tools for FUO was determined using not only 
clinical manifestations and laboratory data, but imaging 
studies (i.e., computed tomography) as well [11].
Despite continuous efforts to confirm the diagnostic yield 
of BM biopsy during investigations of FUO, no studies have 
been currently published regarding age factors affecting the 
diagnostic yield of BM biopsies in FUO. The diagnostic 
yield of BM biopsies in children is important for deciding 
whether BM biopsies should be performed; the procedure 
itself is too invasive for children and hard to perform be-
cause of the need for anesthesia under poor general con-
ditions (i.e., fever or sepsis). Therefore, we identified clin-
ical and laboratory factors, especially age, to determine the 
predictive efficacy for increasing positive findings in BM bi-
opsies and the cause of FUO.
Materials and Methods
The medical records of 150 patients, hospitalized in the 
Yonsei University Health System as the tertiary university 
hospital, between January 1, 2008, and June 30, 2013, who 
underwent BM biopsies were reviewed to determine the 
cause of FUO.
The newer definition of FUO was used in this study: (1) 
3 outpatient visits, (2) 3 days of hospitalization without a 
clear cause, or (3) 1 week of “intelligent and invasive” am-
bulatory investigations [2]. Patients with a known HIV in-
fection, history of hematological malignant disease, or those 
undergoing immunosuppressive therapy or organ trans-
plantation were excluded.
The 150 patients were categorized into either the ‘BM spe-
cific diagnostic group’ or ‘non-diagnostic group’ by evaluat-
ing the BM biopsy pathology of each patient. A BM specific 
diagnosis was defined when all specific diagnoses were con-
firmed by the BM biopsy examination (i.e., leukemia, lym-
phoma, myeloproliferative disease, myelodysplastic syn-
drome, aplastic anemia, hemophagocytic lymphohistiocy-
tosis, and BM involvement of solid tumors).
1) Diagnostic workup
A standardized diagnostic workup was conducted to con-
firm that the FUO included medical history reviews, clinical 
physical examinations, blood tests, urinalysis with urine cul-
tures, chest radiography, abdominal ultrasonography, con-
trast-enhanced chest computed tomography (CT), abdomi-
nal-pelvic CT, positron emission tomography (PET)-CT, and 
echocardiogram. The routine blood test included a complete 
blood cell count with a differential leukocyte count, routine 
blood chemistry analysis (including lactate dehydrogenase 
and ferritin), erythrocyte sedimentation rate, C-reactive pro-
tein, blood cultures, and serology tests for cytomegalovirus 
and Epstein-Barr virus.
In our study, patients with anemia were determined us-
ing hemoglobin levels according to the following age-spe-
cific criteria: hemoglobin ＜10 g/dL in patients ＜6 years, 
＜11 g/dL in patients aged 6-15 years, and ＜12 g/dL in 
patients ＞15 years. Patients who had both leukocytopenia 
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Table 1. Baseline variables of the study patients (n=150)
Characteristic Value (Mean±SD, %)
Age (Mean±SD, yr)
Sex
  Male
  Female
Symptoms
  URI (cough, sputum, rhinorrhea)
  Bone pain
  Rash
  GI (nausea, vomiting, diarrhea)
  Weight loss
  Sweating 
Signs
  Splenomagaly
  Lymphadenopathy
  Hepatomegaly 
38.4±26.6
 
 86 (57.3)
 64 (42.7)
 
 59 (39.3)
 44 (29.3)
 34 (22.7)
 22 (14.7)
  7 (4.7)
  5 (3.3)
 
 32 (21.3)
 20 (13.3)
 13 (8.7)
UR, upper respiratory infection; GI, gastrointestinal.
Table 2. Final diagnoses determined by bone marrow examination
Final diagnosis Patinets, No. (n=24)
Leukemia
  Acute lymphoblastic leukemia
  Acute myeloid leukemia
Non-Hodgkin lymphoma 
  Peripheral T-cell lymphoma
  Diffuse large B cell lymphoma
  NK/T cell lymphoma
  Burkitt lymphoma 
  Intravascular lymphomatosis B cell
  Follicular lymphoma
Myeloproliferative disorder
  Chronic myeloid leukemia
Myelodysplastic syndrome
Solid malignant neoplasms 
  Neuroblastoma
Aplastic anemia 
Hemophagocytic lymphohistiocytosis
Total
 1 (4.2)
 0
 1
11 (45.8)
 1
 6
 1
 1
 1
 1
 2 (8.3)
 2
 2 (8.3)
 1 (4.2)
 1
 1 (4.2)
 6 (25)
24 (100%)
(i.e., white blood cell count ＜4,000/L) and thrombocyto-
penia (i.e., platelet count ＜10×103/L) were defined as 
having a ‘bicytopenia’ state.
All imaging studies were categorized either as normal or 
abnormal. In the echocardiogram pericardial effusion, peri-
carditis and vegetation were considered abnormal. Abnormal 
results of the chest and abdominal image (i.e., chest X-ray, 
US, CT, PET-CT, echocardiogram) included hepatomegaly, 
splenomegaly, significant lymphadenopathy (appearing as 
non-reactive), definite infectious focus, and suspicious 
malignancies. However, only suspicious malignancies in the 
PET-CT image were categorized as abnormal.
2) Statistical analysis
Continuous variables were statistically represented as 
means with standard deviations. Univariate analyses, con-
ducted to evaluate the differences between the groups 
based on baseline clinical variables, were performed with 
the Student t-tests for continuous variables and Chi-square 
test for categorical variables. We also calculated the odds 
ratios (OR) along with their P-values and 95% confidence 
intervals (CI) in the univariate analyses. In the multivariate 
analysis, a binary logistic regression test was applied to se-
lect variables, which were considered as independent and 
predictable factors for effective BM biopsy. All statistical 
evaluations in this study were conducted using SPSS stat-
istical software version 18.0.0 (SPSS Inc., Chicago, IL, 
USA). All results with a P-value ＜0.05 were regarded to 
be statistically significant.
Results
1) Demographics
The baseline characteristics and variables of the 150 pa-
tients (86 men and 64 women), with an age from 1 year 
old to 89 years old, are summarized in Table 1. The most 
common symptom and sign of our population were upper 
respiratory infection symptoms and splenomegaly, respectively.
2) Diagnoses after bone marrow biopsy for patients with fever 
of unknown origin
Hematological malignant disorders were observed to be 
the most dominant diagnosis, which included non-Hodgkin’s 
lymphoma (n=11) and hemophagocytic lymphohistiocytosis 
(n=6; Table 2). The final diagnoses were established after 
BM biopsies in 24 patients (16.0%).
3) Risk factors to determine the diagnostic yield of bone 
marrow biopsy
The clinical and biological characteristics, considered as 
predictable factors for deciding whether or not to perform 
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Table 4. Clinical and laboratory predictive parameters with bone marrow biopsy contribution
Clinical & biological characteristic
Adult groupa) Child groupa)
Odds ratio (95% Cl) P-valueb) Odds ratio (95% Cl) P-valueb)
Sex 
Anemiac)
Leukocytopeniad)
Thrombocypoteniad)
Bicytopeniad)
C-reactive protein ＞100 (mg/L)
Lactate dehydrogenase ＞350 (IU/L)
Ferritin ＞500 (ng/mL)
Abnormal echocardiography
Chest or abdomen image abnormality
Suspected malignancy in PET-CT
1.54 (0.57-4.15)
5.49 (1.81-16.6)
2.03 (0.70-5.92)
2.81 (1.01-7.84)
 3.40 (1.03-11.26)
2.54 (0.95-7.80)
3.53 (1.29-9.70)
 8.08 (1.75-37.32)
12.75 (2.16-75.30)
 3.17 (0.67-14.87)
12.53 (3.08-51.02)
0.46
＜0.05b)
0.24
0.05
0.07
0.07
＜0.05b)
＜0.05b)
＜0.05b)
0.23
＜0.05b)
1.10 (0.99-1.22)
3.07 (0.25-38.6)
4.25 (0.36-50.4)
 7.83 (0.54-113.0)
 12.0 (0.74-194.6)
0.94 (0.88-1.00)
1.18 (0.98-1.11)
 8.40 (0.63-112.1)
-
 7.09 (0.59-85.69)
-
0.55
0.39
0.26
0.08
0.16
0.66
＜0.05b)
0.14
-
0.15
-
a)Adult group, ＞18 years old; Child group, ≤18 years old. b)Statistically significant for BM diagnostic (P＜0.05). c)Anemia: under 
6 years old; ＜10 (g/dL), 6 years to 15 years old; ＜11 (g/dL), over 16 years old; ＜12 (g/dL). d)Leukocytopenia, Leukocytes 
＜4,000(/L); Thrombocypotenia, Plt ＜10×103 (/L); Bicytopenia, Leukocytes ＜4,000(/L) and Plt ＜10×103 (/L).
Table 3. Clinical and biological characteristics of patients with bone marrow biopsy contribution
Characteristic
Adult groupa) Child groupa)
BM diagnostic
(n=21, %)
BM 
non-diagnostic
(n=76, %)
P-valueb)
BM diagnostic
(n=3, %)
BM 
non-diagnostic
(n=50, %)
P-valueb)
Age (Mean±SD, yr)
URI
Bone pain
Lymphadenopathy
Hepatomegaly
Splenomegaly
Abnormal echocardiography
Chest or Abdomen image abnormality
Suspected malignancy in PET-CT
Leukocyte count (/L)
Lymphocyte count (/L)
Hb (g/dL)
Platelet (×103/L)
CRP (mg/L)
LDH (IU/L)
Ferritin (ng/mL)
58.7±14.0
6 (28.6%)
7 (33.3%)
2 (9.5%)
3 (14.3%)
5 (23.8%)
6 (28.6%)
19 (90.5%)
8 (38.1%)
9,952.9±11,687.1
1,433.7±1,115.9
10.4±2.1
148.8±119.5
107.9±88.5
385.8±213.7
1,674.1±1,879.3
 54.0±18.0
28 (36.8%)
28 (36.8%)
12 (15.8%)
6 (7.9%)
19 (25.0%)
2 (2.6%)
57 (75.0%)
5 (6.6%)
10,467.5±7,098.0
 1,577.4±1,991.1
12.0±2.2
 265.5±184.5
 73.0±92.0
 306.8±178.0
 1,473.5±2,001.0
  0.27
  0.48
  0.77
  0.47
  0.37
  0.91
＜0.05b)
  0.31
＜0.05b)
  0.80
  0.77
＜0.05b)
＜0.05b)
  0.12
  0.09
  0.69
4.2±1.9
    1 (33.3%)
    2 (66.7%)
0
    1 (33.3%)
    1 (33.3%)
0
    2 (66.6%)
    1 (33.3%)
4,463.3±4,409.4
2,256.7±1,898.7
10.3±1.5
150.3±107.3
11.0±14.0
592.7±148.5
1,759.3±1,440.2
8.2±4.6
   24 (48.0%)
    7 (14.0%)
    6 (16.0%)
   3 (6.0%)
    7 (14.0%)
0
   11 (22.0%)
0 
8,138.4±8,418.4
2,009.2±1,313.8
11.7±1.5
347.5±180.7
25.2±33.3
338.4±183.0
  875.5±2,106.6
  0.15
  0.62
＜0.05b)
  0.52
  0.08
  0.36
-
  0.15
  0.08
  0.46
  0.76
  0.14
  0.07
  0.47
＜0.05b)
  0.49
BM, Bone marrow; Hb, Hemoglobin; CRP, C-reactive protein; LDH, Lactate dehydrogenase.
a)Adult group, ＞18 years old; Child group, ≤18 years old. b)Statistically significant for BM diagnostic (P＜0.05).
BM biopsy, are listed in Table 3. Initial hemoglobin and 
platelet levels were significantly lower in the BM diagnostic 
group than the non-diagnostic group in adult group. 
Lactate dehydrogenase levels were higher in the BM diag-
nostic group compared to the non-diagnostic group in child 
group. The symptoms (i.e., rash and bone pain) and signs 
(i.e., lymphadenopathy, hepatomegaly, and splenomegaly) 
of the patients were not significantly different, excluding 
bone pain in child group. Most imaging studies were more 
likely to be abnormal in adult BM diagnostic group.
Anemia, thrombocytopenia (platelet ＜10×103/L), bicy-
topenia (leukocytes ＜4,000/L and platelet ＜10×103/L), 
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Table 5. Multivariate analysis of patients with useful bone 
marrow biopsy result
Variables
BM - specific diagnosis
Hazard ratio P-valuea)
Sex
 
Anemia
 
Bicytopenia
 
LDH
 
Age
 
 
Image
abnormalityb)
Female
Male
Normal
Abnormal
Normal
Abnormal
≤350 IU/L
＞350 IU/L
18-40 years old
＜18 years old
≥40 years old
Normal
Abnormal
 1
 1.399
 1
 8.659
 1
 5.21
 1
10.71
 1
 3.11
 8.227
 1
 2.912
 
0.585
 
＜0.05a)
 
＜0.05a)
 
＜0.05a)
 
0.381
0.062
 
0.17
LDH, Lactate dehydrogenase.
a)Statistically significant for BM diagnostic (P＜0.05). b)Image ab-
normality; Chest or Abdomen image abnormality (ultrasonography 
or CT).
increased LDH levels (＞350 IU/L), increased ferritin levels 
(＞500 ng/mL), and imaging abnormalities were also sig-
nificant factors for predicting effective BM biopsy in adult 
group (all P＜0.05; Table 4). However, only increased LDH 
levels (＞350 IU/L) was significant factors for predicting ef-
fective BM biopsy in child group.
4) Multivariate analysis for risk factors
For the multivariate analysis with logistic regression anal-
ysis, we selected 6 variables that were considered as pre-
dictive factors (i.e., sex, age, anemia, bicytopenia, LDH, 
and image abnormality). The young adult group (18-40 
years old; young adult [AYA] age group) was the lowest 
probability for a positive BM diagnostic yield for FUO. The 
children and adolescent group under 18 years old had an 
increased tendency of positive BM biopsy finding (hazard 
ratio [HR], 3.11; 95% confidence interval [CI], 0.25-39.59) 
compared to the AYA group; however, this relationship 
was not significant. And we also observed that under 18 
years old group was safer from the tendency of BM biopsy 
diagnosis compared to over 40 years old group (HR, 8.227; 
95% CI, 0.90-75.36). Low hemoglobin levels (HR, 8.66; 95% 
CI, 2.32-32.40), bicytopenia (HR, 5.21; 95% CI, 1.34-20.26), 
and increased LDH levels (HR, 10.71; 95% CI, 2.78-41.29) 
were determined to be independent predictive factors for 
diagnostic BM biopsy (P＜0.05; Table 5).
Discussion
In this study, we tried to confirm the diagnostic yield of 
BM biopsy in patients with FUO in all age groups. Until 
now, numerous studies that have been published regarding 
effective BM biopsies in patients with FUO were generally 
limited to adult patients [7,10-13]. However, BM biopsies 
are relatively difficult to conduct in young patients because 
of sedation, airway problems, and poor general conditions 
associated with systemic inflammatory response syndrome 
during FUO. However, BM biopsies should be performed 
despite procedural difficulties, if proven effective in young-
er patients with FUO, due to the higher incidences of hem-
atological malignant diseases (i.e., acute lymphoblastic leu-
kemia or lymphoma) in the BM of pediatrics patients com-
pared to adult [14-16].
During the past decades, almost all large FUO studies re-
garding BM biopsy yields were conducted in adult patients 
[7,10-13]. In the 2 most recent reports, which were aimed 
at determining predictive factors of diagnostic BM biopsies, 
the study population included only adult patients [10,11]. 
Numerous studies involving pediatric participants have 
been published; however, the results of these studies were 
limited in the etiology or prognosis of FUO retrospectively 
[17,18]. Only a few studies have been published regarding 
the diagnostic yield of basic procedures in young patients 
with FUO. Especially, the report that focusing the diag-
nostic role of BM Biopsies in FUO was unprecedented. And 
in most reports, descriptions about the role of BM biopsies 
were limited to secondary option of FUO workup [19]. 
Hasan et al. was the only mentioned that several invasive 
procedures, including BM biopsies, were effective in 29% 
of pediatric patients with FUO [20]. Until now, no reports 
have been conducted to elucidate the diagnostic yield of 
BM biopsies in pediatric patients with FUO patients and the 
difference in the diagnostic yield of BM biopsies according 
to age (i.e., childhood vs. adulthood). Deciding whether 
or not to perform BM biopsies is dependent upon age fac-
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tors, because of the higher incidence of hematologic malig-
nancies and the difficulty and safety issues in pediatric age 
related to performing BM biopsies under anesthesia.
In this study, we determined the yield or efficacy of BM 
biopsies for diagnosing FUO in 3 age groups (i.e., children 
＜18 years, 18-40 years or AYA group, and old age group 
＞40 years old). We found that in spite of high incidence 
of hematological malignant diseases which can be con-
firmed by BM biopsies in younger patients, the pediatric 
group (＜18 years old) had the lower probability for a pos-
itive BM diagnostic yield for FUO comparing the old age 
group (＞40 years old). Therefore, the requirements for BM 
biopsies should be re-modified by considering the efficacy 
and safety aspects of the pediatric group (＜18 years old).
We observed that anemia, bicytopenia, and increased 
LDH levels were independent predictive parameters for di-
agnostic BM biopsy in multivariate analysis. Hot et al. re-
vealed that lower hemoglobin levels and platelet counts 
were associated with a higher possibility of diagnostic BM 
biopsies [10]. The authors of this study performed the basic 
FUO workup, including medical history reviews, clinical 
physical examinations, laboratory results, but not imaging 
investigations. Recently, CT was regarded as an initial in-
vestigation tool for evaluating FUO because of its relatively 
high diagnostic profit [3,13]. Furthermore, Ben-Baruch et al. 
reviewed the diagnostic yields of BM biopsies in extensive 
FUO workup processes using CT images [11]. In their multi-
variate analysis, lower hemoglobin and increased LDH lev-
els were confirmed as positive indicators of diagnostic BM 
biopsies. Our results from the multivariate analysis were 
similar to those of recently published reports; lower hemo-
globin levels, bicytopenia, and increased LDH levels were 
independent predictive factors for effective BM biopsies. 
The final diagnoses in this study, which were confirmed by 
BM biopsies, were mostly hematologic disorders. Laboratory 
factors (i.e., lower hemoglobin levels, bicytopenia, or in-
creased LDH levels) all suggested bone marrow involve-
ments of hematologic disorders, which was consistent with 
previous studies.
For investigations of FUO, X-ray and ultrasonography are 
regarded as first line imaging workup followed by CT and 
magnetic resonance imaging (MRI). These primary anatom-
ic imaging studies play critical roles in diagnosing or guid-
ing the biopsy in patients with FUO; however, the sensi-
tivity of these initial imaging tools is inferior [7]. Recently, 
the contribution of PET/CT for FUO evaluations has in-
creased because of its usefulness in the field of oncology 
and its ability to determine nonspecific inflammation and 
malignancy. Kouijzer et al. observed a high sensitivity 
(89-100%) and usefulness of PET/CT imaging for FUO in-
vestigations in a review of 10 past studies related to PET/CT 
in FUO [21]. In one of the pediatric studies, PET or PET/CT 
was determined to be clinically useful (45%) as a diagnostic 
tool for evaluating pediatric FUO and unexplained in-
flammation [22]. However, PET/CT was not proved to be 
an independent factor for predicting positive BM biopsy 
findings in this study, which implies that the probability of 
hematologic malignancies was high. These findings were 
not consistent with previously reports, probably due to sev-
eral factors and biases. Firstly, X-ray, ultrasonography, CT, 
and PET/CT images were used simultaneously during the FUO 
workup and were not conducted sequentially. Therefore, the 
efficacy of PET/CT might be biased. Secondly, diagnoses 
would be direct and additional invasive procedures (i.e., 
BM biopsies) can be avoided if signs of malignancy or FUO 
are observed in the PET/CT images.
A limitation of this study was that it was a retrospective 
study, which was conducted at a single center. However, 
strengths of this study were that the diagnostic procedures 
were conducted in a homogeneous physicians group at a 
tertiary center and focused on the BM biopsy yield in the 
modern era using various effective laboratories and imaging 
workups. Moreover, we focused on age factors to de-
termine the BM biopsy diagnostic yield, which had not 
been studied previously according to the best of our 
knowledge.
In conclusion, certain laboratory abnormalities that de-
termined the diagnostic yield of BM biopsies were con-
firmed in this study. In addition to such abnormalities, the 
BM biopsy can be less likely to yield occult malignancies 
in pediatric group (＜18 years old) comparing the older age 
group (＞40 years old). 
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